Senetek PLC and CP Pharmaceuticals Collaborate on Impotence Therapy

Senetek PLC (Napa, CA) and CP Pharmaceuticals Ltd. (Wrexham, UK), recently announced that the two companies had entered into a contract manufacturing agreement whereby CP will manufacture INVICORP, Senetek's injectable therapy for male erectile dysfunction. CP is a major contract manufacture of prescription pharmaceutical products and currently a manufacturer for four of the world's top ten pharmaceutical companies and two major biotechnology companies, while Senetek PLC is a science-driven biotechnology company providing solutions to aging-related healthcare problems.

At the signing agreement in Wrexham, Anthony J. Cataldo, chairman and CEO of Senetek, expressed confidence that CP pharmaceuticals will "meet the exacting requirements of the regulatory bodies in the major countries of the world."

CP Pharmaceutical's CEO, Charles Savage, confirmed Cataldo's assertion: "CP's… product manufacturing facility was designed to meet the requirements of the United States Food and Drug Administration (FDA) as well as of the UK's Medicines Control Agency (MCA). We… look forward to supporting Senetek in launching its new product."